David A. Siegel Palatin Technologies Inc Transaction History

Two Sigma Advisers, LP

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.34 - $0.86 $31,824 - $80,496	-93,600 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$0.44 - $0.63 $19,008 - $27,216	43,200 Added 85.71%	93,600 $41,000
Q2 2021 Aug 16, 2021	SELL	$0.48 - $0.72 $100,368 - $150,552	-209,100 Reduced 80.58%	50,400 $31,000
Q1 2021 May 17, 2021	BUY	$0.68 - $1.25 $130,424 - $239,750	191,800 Added 283.31%	259,500 $179,000
Q4 2020 Feb 16, 2021	BUY	$0.38 - $0.78 $25,726 - $52,806	67,700 New	67,700 $46,000

Q3 2020 Nov 16, 2020	SELL	$0.47 - $0.64 $65,004 - $88,516	-138,307 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.41 - $0.73 $14,842 - $26,426	36,200 Added 35.45%	138,307 $71,000
Q1 2020 May 15, 2020	BUY	$0.36 - $0.79 $30,409 - $66,732	84,471 Added 478.97%	102,107 $43,000
Q4 2019 Feb 14, 2020	BUY	$0.75 - $0.89 $13,227 - $15,696	17,636 New	17,636 $14,000
Q3 2019 Nov 14, 2019	SELL	$0.78 - $1.09 $16,720 - $23,365	-21,436 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$0.98 - $1.64 $7,973 - $13,343	8,136 Added 61.17%	21,436 $25,000
Q1 2019 May 15, 2019	SELL	$0.67 - $1.01 $3,886 - $5,858	-5,800 Reduced 30.37%	13,300 $13,000
Q4 2018 Feb 14, 2019	SELL	$0.63 - $1.0 $17,451 - $27,700	-27,700 Reduced 59.19%	19,100 $14,000
Q3 2018 Nov 14, 2018	SELL	$0.88 - $1.1 $11,176 - $13,970	-12,700 Reduced 21.34%	46,800 $47,000
Q2 2018 Aug 14, 2018	BUY	$0.91 - $1.45 $10,010 - $15,950	11,000 Added 22.68%	59,500 $58,000
Q1 2018 May 15, 2018	BUY	$0.84 - $1.18 $30,408 - $42,716	36,200 Added 294.31%	48,500 $53,000
Q4 2017 Feb 14, 2018	BUY	$0.68 - $1.0 $8,364 - $12,300	12,300	12,300 $11,000

3.02K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $18.1M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.